Ligand's Captisol technology is a key platform, focusing on enhancing the solubility, stability, and bioavailability of various drugs. This technology is used in several commercial products, including Veklury for COVID-19 treatment, and is also applied in formulations for cancer treatments like Kyprolis and Evomela. Research and development efforts are focused on expanding the application of Captisol to new drug candidates and improving existing formulations. The technology addresses the challenge of delivering poorly soluble drugs, improving patient outcomes by increasing drug efficacy and reducing side effects. Captisol's market positioning is strong due to its proven track record and partnerships with major pharmaceutical companies. Future opportunities include expanding into new therapeutic areas and developing advanced drug delivery systems. Regulatory and clinical aspects involve rigorous testing and FDA approval for each Captisol-enabled product. Partnerships are crucial for commercialization and include collaborations with pharmaceutical companies for product development and licensing.

This segment focuses on Ligand's diverse portfolio of royalty-generating products and partnerships with other pharmaceutical companies. Ligand receives royalties from the sales of products developed and commercialized by its partners, including Kyprolis, Evomela, and Veklury. Research and development activities are focused on identifying and supporting promising drug candidates through licensing agreements and collaborations. The segment leverages Ligand's technologies and expertise to facilitate the development and commercialization of innovative medicines across various therapeutic areas, including oncology, infectious diseases, and hematology. The impact on patients is significant, as these partnerships bring life-saving and life-improving drugs to market. Market positioning is driven by the success of its partners' products and the strength of its intellectual property portfolio. Future opportunities include expanding the royalty portfolio through new partnerships and licensing agreements. Regulatory and clinical aspects are managed by the partners, with Ligand providing support and expertise. Partnerships are the core of this segment, with collaborations with major pharmaceutical companies driving revenue and growth.

The OmniAb platform is a key technology for discovering and developing fully human antibodies. This segment focuses on enabling the discovery of therapeutic antibodies for various diseases. Research and development activities include continuous improvement of the platform and the generation of novel antibody candidates. The platform utilizes advanced technologies to identify and optimize antibodies with high affinity and specificity. Therapeutic areas covered include oncology, immunology, and infectious diseases. The patient impact is significant, as the platform contributes to the development of new antibody-based therapies. Market positioning is strong due to the platform's ability to generate high-quality antibodies and its partnerships with leading pharmaceutical companies. Future opportunities include expanding the platform's capabilities and entering into new partnerships. Regulatory and clinical aspects involve the development and testing of antibody candidates. Partnerships are essential for commercialization and include collaborations with pharmaceutical and biotechnology companies.